Avoid Mass Spec-ulation: Use References
The introduction of a global reference method for measuring beta-amyloid biomarkers in cerebrospinal fluid could harmonize Alzheimer’s diagnostic results
Roisin McGuigan |
Analysis of beta-amyloid in the cerebrospinal fluid (CSF) is an increasingly common method for early diagnosis of Alzheimer’s disease (AD), and is seeing use in both clinical and research settings. But just how accurate are these tests? A reference method for harmonizing beta-amyloid measurement, developed by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division Working Group on CSF proteins, has now been formally classified as the international standard, in order to address current issues with diagnostic testing.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine